Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
29 Dezember 2023 - 1:16PM
Edgar (US Regulatory)
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES
EXCHANGE ACT OF 1934
December, 2023
Commission File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
¨
No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
Date: December 29, 2023 |
By: |
/s/ K Randhir Singh |
|
|
Name: K Randhir Singh |
|
|
Title: Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
December 29, 2023
National Stock Exchange of India Ltd. (Scrip Code:
DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Ref: Disclosure
pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
Sub: Acquisition
of securities by a wholly-owned step-down subsidiary company
Dear Sir/ Madam,
Pursuant to Regulation 30 read with Schedule III of
the SEBI Listing Regulations, we would like to inform that Dr. Reddy’s Laboratories, Inc., wholly-owned step-down subsidiary of
the Company, has acquired 1,014,442 Preferred A-1 shares of Edity Therapeutics Limited (“Edity”), a biotechnology company,
equivalent to 6.46% of the shareholding of Edity on fully diluted basis.
The details required under Regulation 30 of the SEBI
Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above acquisition
is given in Annexure enclosed herewith.
Kindly take the above on your record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Encl.: as above
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
Annexure
Disclosure under Part A Para A(i) of Schedule III
read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
S. No. |
Particulars |
Details |
1. |
Name of the target entity, details in brief such as size, turnover etc. |
Edity Therapeutics Ltd. (“Edity”)
Brief description: Edity is an Israel based
development stage biotechnology company focusing on a breakthrough platform technology for intracellular delivery of therapeutic proteins
utilizing immune cells. Therapeutics based on the Edity technology could be useful in multiple therapeutic areas including gene editing,
rare genetic disorders, oncology and inflammation.
Edity has not yet commercialized its technology/products
and hence does not generate any revenues. |
2. |
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” |
Acquisition does not fall
within the purview of related party transactions.
None of the promoter/promoter
group/group companies have any interest in Edity. |
3. |
Industry to which the entity being acquired belongs |
Biotechnology and Life Sciences Industry. |
4. |
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) |
The funds invested by Dr. Reddy’s would be utilized by Edity to further develop its technology platform. This includes performing pre-clinical studies for safety and efficacy evaluation, securing intellectual property through patent filings, and exploring licensing opportunities, collaborations, and market entry strategies to optimize the commercial viability of Edity's technology platform. |
5. |
Brief details of any governmental or regulatory approvals required for the acquisition |
The Preferred A-1 shares have been allotted on December 28, 2023. No further governmental or regulatory approvals is required. |
6. |
Indicative time period for completion of the acquisition |
The Preferred A-1 shares have been allotted on December 28, 2023. |
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
7. |
Consideration - whether cash consideration or share swap or any other form and details of the same |
Cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of USD 2 Million to Preferred A-1 Shares |
8. |
Cost of acquisition and/or the price at which the shares are acquired |
USD $1.9715 per Preferred A-1 share. |
9. |
Percentage of shareholding/ control acquired and/ or number of shares acquired |
1,014,442 Preferred A-1 shares, equivalent to 6.46% of Edity share capital on a fully diluted basis. |
10. |
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) |
Edity is an Israel based development stage biotechnology
company focusing on a breakthrough platform technology for intracellular delivery of therapeutic proteins utilizing immune cells. Therapeutics
based on the Edity technology could be useful in multiple therapeutic areas including gene editing, rare genetic disorders, oncology and
inflammation. Edity was incorporated in Israel on October 22, 2019.
Edity has not yet commercialized its technology/products
and hence does not generate any revenues. Accordingly, last 3 years turnover is nil. |
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Mai 2023 bis Mai 2024